| 摘要 |
The present invention relates to: a novel bis-amide derivative compound or a pharmaceutically acceptable salt thereof; a preparation method therefor; and a pharmaceutical composition for preventing or treating diseases caused by hepatitis C virus infection and a dietary supplement for preventing or alleviating diseases caused by hepatitis C virus infection, containing the bis-amide derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. The novel bis-amide derivative compound of the present invention, particularly WJCPA-126, specifically binds to the catalytic site of CypA to effectively inhibit the activity of an isomerase, and the duration of the inhibitory effect can be increased since WJCPA-126 binds to CypA with a high binding force exhibiting a low dissociation rate (Koff). Accordingly, WJCPA-126 has nontoxic and non-immunosuppressive characteristics and can effectively inhibit HCV replication in vitro and in vivo model systems. In addition, WJCPA-126 reactivates the host interferon response through an increase in the expression of IFN stimulated genes (ISGs) and the inhibition of interleukin-8 (IL-8) secretion. Therefore, a series of the bis-amide derivatives including WJCPA-126 can be useful as a novel type CypA inhibitor exhibiting antiviral efficacy. |
